AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9864835 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. TNFR55-IgG1 50 mg monthly after loading dose of 100 mg
Number of subjects: 218
Study 9864835 — intervention group
Group type: COMPARATOR
Intervention: i.v. placebo
Number of subjects: 218
Study 7890253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (1 ml/kg, 95% ethanol)
Number of subjects: 7
Study 7890253 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric carbohydrate drink
Number of subjects: 7
Study 2197536 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 300 mg of pentamidine every 28 days
Number of subjects: 160
Study 2197536 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of placebo (300 mg of Na isethionate) every 28 days
Number of subjects: 160
Study 343479 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural injection of 2 ml (80 mg) methyl prednisolone
Number of subjects: 51
Study 343479 — intervention group
Group type: COMPARATOR
Intervention: Control group received 2 ml normal saline solution
Number of subjects: 51
Study 7244394 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (O)
Number of subjects: 36
Study 7244394 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal failure under hemodialysis (H)
Number of subjects: 36
Study 7244394 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia (P)
Number of subjects: 36
Study 7244394 — intervention group
Group type: COMPARATOR
Intervention: Normal personnel (N)
Number of subjects: 36
Study 7244394 — intervention group
Group type: COMPARATOR
Intervention: Interstitial lung disease (CILD)
Number of subjects: 36
Study 31269394 — intervention group
Group type: EXPERIMENTAL
Intervention: CT3RGDcT3AYJCT3 (J: D‐Leu)
Number of subjects: 0
Study 31269394 — intervention group
Group type: EXPERIMENTAL
Intervention: CT3RGDcT3AYaCT3
Number of subjects: 0
Study 31269394 — intervention group
Group type: EXPERIMENTAL
Intervention: CT3RGDcT3AWGCT3
Number of subjects: 0
Study 31269394 — intervention group
Group type: COMPARATOR
Intervention: knottin-RGD
Number of subjects: 0
Study 27810148 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided extrathoracic sub-paraspinal block
Number of subjects: 10
Study 27810148 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 26340540 — intervention group
Group type: EXPERIMENTAL
Intervention: Zephyr® EBV treatment in upper lobe (n=45)
Number of subjects: 331
Study 26340540 — intervention group
Group type: EXPERIMENTAL
Intervention: Zephyr® EBV treatment in lower lobe (n=15)
Number of subjects: 331
Study 24042256 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81-100 mg daily)
Number of subjects: 2539
Study 24042256 — intervention group
Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 2539
Study 21832272 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline for cigarette smoking cessation
Number of subjects: 280
Study 21832272 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 280
Study 19848195 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingxuan Tiaoya Recipe (QXTYR) + perindopril tablet
Number of subjects: 87
Study 19848195 — intervention group
Group type: COMPARATOR
Intervention: Simulator of QXTYR + perindopril tablet
Number of subjects: 87
Study 17563125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg FDT
Number of subjects: 36
Study 17563125 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine 5 mg
Number of subjects: 36
Study 17563125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15062907 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Information Leaflet (PIL)
Number of subjects: 317
Study 15062907 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 317
Study 12165594 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body hypothermia (target temperature of 34.5 degrees C for 72 hours)
Number of subjects: 19
Study 12165594 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 19
Study 12165594 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body hypothermia
Number of subjects: 19
Study 10091410 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Peripheral blood stem cells (PBSC) collected after induction and consolidation chemotherapy, followed by ABSCT immediately thereafter.
Number of subjects: 50
Study 10091410 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: PBSC collected after consolidation alone, followed by intermediate dose cytarabine (Ara‐C 1 g/m2/12 h x3 days) and mitoxantrone (12 mg/m2/d x3 days) as early intensification before ABSCT.
Number of subjects: 50
Study 10091410 — intervention group
Group type: COMPARATOR
Intervention: Group A
Number of subjects: 50
Study 10091410 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 50
Study 10091410 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 7844085 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of salbutamol plus beclomethasone
Number of subjects: 22
Study 7844085 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol alone
Number of subjects: 22
Study 7844085 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone alone
Number of subjects: 22
Study 2347981 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training (8 sessions + 4 booster sessions)
Number of subjects: 0
Study 2347981 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study 624427 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cortisone
Number of subjects: 38
Study 31485929 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided transversus abdominis plane blocks (UTAP)
Number of subjects: 60
Study 30587521 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid solution
Number of subjects: 46
Study 30587521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet (sucrose) solution
Number of subjects: 46
Study 30587521 — intervention group
Group type: EXPERIMENTAL
Intervention: Salty (NaCl) solution
Number of subjects: 46
Study 30587521 — intervention group
Group type: COMPARATOR
Intervention: Paraffin oil mixture or water (control)
Number of subjects: 46
Study 30587521 — intervention group
Group type: EXPERIMENTAL
Intervention: Five FFA solutions
Number of subjects: 46
Study 30587521 — intervention group
Group type: COMPARATOR
Intervention: Paraffin emulsion (control)
Number of subjects: 46
Study 26771291 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (8 weeks treatment)
Number of subjects: 70
Study 26771291 — intervention group
Group type: COMPARATOR
Intervention: CBT-waitlisted subjects (control)
Number of subjects: 70
Study 26033648 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC (vacuum assisted closure)
Number of subjects: 40
Study 26033648 — intervention group
Group type: COMPARATOR
Intervention: Bogota bag
Number of subjects: 40
Study 23787939 — intervention group
Group type: EXPERIMENTAL
Intervention: Early digit mobilization
Number of subjects: 22
Study 23787939 — intervention group
Group type: COMPARATOR
Intervention: Control (usual home programmes)
Number of subjects: 22
Study 23787939 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 22115379 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution Focused Therapy (SFT)
Number of subjects: 29
Study 22115379 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy (PST)
Number of subjects: 29
Study 22115379 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 29
Study 19380429 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth HIV intervention plus a parental monitoring/communication/HIV education intervention
Number of subjects: 1360
Study 19380429 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth HIV intervention plus a parental goal-setting intervention
Number of subjects: 1360
Study 19380429 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental protection intervention plus parental goal-setting intervention
Number of subjects: 1360
Study 19380429 — intervention group
Group type: COMPARATOR
Intervention: Focus on Youth in the Caribbean groups
Number of subjects: 1360
Study 16892911 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine efficacy against infection and disease
Number of subjects: 0
Study 16892911 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric kernel smoothing
Number of subjects: 0
Study 16892911 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally parametric penalized splines
Number of subjects: 0
Study 16892911 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully parametric cubic linear splines
Number of subjects: 0
Study 15572812 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (250 mcg, 3 puffs)
Number of subjects: 60
Study 15572812 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (100 mcg, 3 puffs)
Number of subjects: 60
Study 15572812 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Terbutaline and Salbutamol
Number of subjects: 60
Study 12214823 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized version of the Tower of Hanoi puzzle
Number of subjects: 0
Study 12214823 — intervention group
Group type: COMPARATOR
Intervention: Wooden version of the Tower of Hanoi puzzle
Number of subjects: 0
Study 9633848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy
Number of subjects: 0
Study 8543621 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Uvitex 2B staining
Number of subjects: 18
Study 8543621 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients without infection)
Number of subjects: 18
Study 2153193 — intervention group
Group type: COMPARATOR
Intervention: CAV (cyclophosphamide, doxorubicin, and vincristine)
Number of subjects: 231
Study 2153193 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVE (CAV plus etoposide)
Number of subjects: 231
Study 348533 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine
Number of subjects: 135
Study 348533 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 135
Study 348533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 29253068 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day for 1 year
Number of subjects: 742
Study 29253068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 742
Study 29253068 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 742
Study 26484952 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 2 sessions per week for 8 weeks
Number of subjects: 26
Study 26484952 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT) - additional sets
Number of subjects: 26
Study 24955550 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron aqueous extract (SAE) 30 mg daily
Number of subjects: 66
Study 24955550 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocin 30 mg daily
Number of subjects: 66
Study 24955550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 21948742 — intervention group
Group type: EXPERIMENTAL
Intervention: Asperger syndrome
Number of subjects: 32
Study 21948742 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 32
Study 20349863 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented metal-on-metal THA
Number of subjects: 195
Study 20349863 — intervention group
Group type: COMPARATOR
Intervention: Metal-on-polyethylene THA
Number of subjects: 195
Study 17091015 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction
Number of subjects: 60
Study 17091015 — intervention group
Group type: COMPARATOR
Intervention: Anteromedial single-bundle ACL reconstruction
Number of subjects: 60
Study 17091015 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral single-bundle ACL reconstruction
Number of subjects: 60
Study 15914936 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers, angiotensin-converting enzyme inhibitors, aldosterone antagonists, and statins
Number of subjects: 0
Study 15914936 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillators (ICD)
Number of subjects: 0
Study 15914936 — intervention group
Group type: COMPARATOR
Intervention: ICD treatment
Number of subjects: 0
Study 14664728 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and Vitamin E
Number of subjects: 0
Study 14664728 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10836327 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg salmeterol
Number of subjects: 42
Study 10836327 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg salmeterol
Number of subjects: 42
Study 10836327 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg salmeterol
Number of subjects: 42
Study 10836327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 7888013 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (600 mg)
Number of subjects: 8
Study 7888013 — intervention group
Group type: COMPARATOR
Intervention: Cortisol (2 micrograms/kg.min for 5 h)
Number of subjects: 8
Study 7888013 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 before normal saline infusion
Number of subjects: 8
Study 7888013 — intervention group
Group type: COMPARATOR
Intervention: Cortisol infusion
Number of subjects: 8
Study 1943180 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbomineral formulation (Articulin‐F)
Number of subjects: 42
Study 1943180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 7032568 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening by mammography and/or clinical examination
Number of subjects: 120000
Study 7032568 — intervention group
Group type: EXPERIMENTAL
Intervention: Education sessions in breast self-examination
Number of subjects: 120000
Study 7032568 — intervention group
Group type: COMPARATOR
Intervention: No additional services beyond conventional diagnostic facilities
Number of subjects: 120000
Study 31183663 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR/Cas9 system with guide RNA 1
Number of subjects: 100
Study 31183663 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR/Cas9 system with guide RNA 2
Number of subjects: 100
Study 31183663 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR/Cas9 system
Number of subjects: 100
Study 29065426 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX-4 or XELOX adjuvant chemotherapy
Number of subjects: 508
Study 27045714 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT (24 one‐hour sessions over 2 months)
Number of subjects: 159
Study 27045714 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited CCRT (same games rotated randomly from simple to moderate levels of training)
Number of subjects: 159
Study 27045714 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT (both arms)
Number of subjects: 159
Study 27045714 — intervention group
Group type: COMPARATOR
Intervention: Passive control group (no training)
Number of subjects: 159
Study 24577971 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuevo Amanecer program (peer-delivered cognitive-behavioral stress management intervention)
Number of subjects: 0
Study 24577971 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuevo Amanecer program
Number of subjects: 0
Study 22395893 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold laser treatment (STLT)
Number of subjects: 25
Study 22395893 — intervention group
Group type: COMPARATOR
Intervention: Threshold laser treatment (TLT)
Number of subjects: 25
Study 21118925 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-mefloquine (AM)
Number of subjects: 300
Study 21118925 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine (DP)
Number of subjects: 300
Study 17558725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal Substitution plus Nutrient Bar (CB)
Number of subjects: 164
Study 17558725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal and Waffle Substitution plus Nutrient Bar (CWB)
Number of subjects: 164
Study 17558725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal Substitution, no Nutrient Bar (CR)
Number of subjects: 164
Study 17558725 — intervention group
Group type: COMPARATOR
Intervention: Control group (CN)
Number of subjects: 164
Study 16351338 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving to Opportunity Program (voucher to move to low-poverty neighborhoods)
Number of subjects: 425
Study 16351338 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-poverty neighborhoods
Number of subjects: 425
Study 16351338 — intervention group
Group type: COMPARATOR
Intervention: High-poverty neighborhoods
Number of subjects: 425
Study 12150481 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin 30 mg/kg
Number of subjects: 0
Study 12150481 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin 15 mg/kg
Number of subjects: 0
Study 12150481 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin 7.5 mg/kg
Number of subjects: 0
Study 12150481 — intervention group
Group type: COMPARATOR
Intervention: Paromomycin 7.5 mg/kg
Number of subjects: 0
Study 10467532 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl-rutosides applied every 3 or 4 hours during the flight
Number of subjects: 51
Study 8778155 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (300 micrograms/d)
Number of subjects: 12
Study 8778155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1330386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10-20 mg once daily
Number of subjects: 219
Study 1330386 — intervention group
Group type: COMPARATOR
Intervention: Felodipine 5-10 mg once daily
Number of subjects: 219
Study 1330386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 219
Study 1330386 — intervention group
Group type: COMPARATOR
Intervention: Felodipine
Number of subjects: 219
Study 2869615 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol in a daily dose of 180 to 240 mg
Number of subjects: 0
Study 29148630 — intervention group
Group type: EXPERIMENTAL
Intervention: BP+LP with rest
Number of subjects: 28
Study 29148630 — intervention group
Group type: EXPERIMENTAL
Intervention: BP+LP no rest
Number of subjects: 28
Study 29148630 — intervention group
Group type: EXPERIMENTAL
Intervention: LP+BP with rest
Number of subjects: 28
Study 29148630 — intervention group
Group type: EXPERIMENTAL
Intervention: LP+BP no rest
Number of subjects: 28
Study 29023875 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (technical endpoint)
Number of subjects: 400
Study 29023875 — intervention group
Group type: COMPARATOR
Intervention: Group B (pursuing AF termination)
Number of subjects: 400
Study 29071875 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-appliance plus tadalafil (10 mg daily for 3 months)
Number of subjects: 90
Study 29071875 — intervention group
Group type: COMPARATOR
Intervention: Oral-appliance
Number of subjects: 90
Study 29071875 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil (10 mg daily for 3 months)
Number of subjects: 90
Study 25772743 — intervention group
Group type: EXPERIMENTAL
Intervention: Next.Step e-therapeutic platform accessed during 24 weeks in addition to standard treatment program
Number of subjects: 94
Study 25772743 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment protocol
Number of subjects: 94
Study 22715808 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of DHA
Number of subjects: 285
Study 22715808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 21521341 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral DHEA 50 mg/day
Number of subjects: 119
Study 21521341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 18773374 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional Psychiatry Budget (RPB) model
Number of subjects: 502
Study 18773374 — intervention group
Group type: COMPARATOR
Intervention: Fee-for-service principle (Control Region)
Number of subjects: 502
Study 16581113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional interferon-alpha 2b combined with oral vitamin E
Number of subjects: 30
Study 16581113 — intervention group
Group type: COMPARATOR
Intervention: Intralesional interferon-alpha 2b alone
Number of subjects: 30
Study 16581113 — intervention group
Group type: COMPARATOR
Intervention: Oral vitamin E alone
Number of subjects: 30
Study 12701068 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meals containing 15,000 retinol equivalents (RE) of vitamin A (as retinyl palmitate) with 40 g of fat (butter)
Number of subjects: 10
Study 12701068 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meals containing 15,000 retinol equivalents (RE) of vitamin A (as retinyl palmitate) with 40 g of fat (olive oil)
Number of subjects: 10
Study 12701068 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meals containing 15,000 retinol equivalents (RE) of vitamin A (as retinyl palmitate) with 40 g of fat (sunflower oil)
Number of subjects: 10
Study 12701068 — intervention group
Group type: COMPARATOR
Intervention: Mixed meals containing 15,000 retinol equivalents (RE) of vitamin A (as retinyl palmitate) with no fat (fat-free meal)
Number of subjects: 10
Study 10928254 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine
Number of subjects: 30
Study 10928254 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 30
Study 9105948 — intervention group
Group type: EXPERIMENTAL
Intervention: High task load visual task
Number of subjects: 0
Study 9105948 — intervention group
Group type: COMPARATOR
Intervention: Low task load visual task
Number of subjects: 0
Study 7963281 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based program with music listening stress reduction techniques at weekly home visits by a music therapist
Number of subjects: 30
Study 7963281 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered program with music listening stress reduction techniques and moderate therapist intervention (weekly telephone call)
Number of subjects: 30
Study 7963281 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 30
Study 3297718 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol (120 mg/day) for 40 days after chemotherapy course
Number of subjects: 40